

## Genomics of Rare Hematologic Cancers

Guest Editor:

### Dr. Francesc Solé

1. MDS Group, Institut de Recerca  
Contra la Leucèmia Josep  
Carreras, 08916 Barcelona, Spain  
2. Microarrays Unit, Institut de  
Recerca Contra la Leucèmia  
Josep Carreras, ICO-Hospital  
Germans Trias i Pujol, Universitat  
Autònoma de Barcelona, 08916  
Badalona, Spain

Deadline for manuscript  
submissions:

**closed (15 June 2022)**


### Message from the Guest Editor

Dear Colleagues,

Leukemias and hematologic cancers occur with less frequency than solid tumors. The most frequent and well-known hematologic cancers could be summarized in chronic and acute myeloid and lymphoid leukemias, myelomas and lymphomas, as well as myelodysplastic syndromes and myeloproliferative neoplasms. In this Special Issue we selected some of the rarest types of hematologic cancers because there are few reviews about these diseases. Now, genomics defines the diagnosis, prognosis, and treatment of most cancers, and we want to present a review of how genomics is useful to define these rare diseases. In this Special Issue we will highlight the genomic information that will be very useful for clinicians to diagnose and treat these patients.

Dr. Francesc Solé  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)